Morphologic Parameters Relevant for Visual Outcome During Anti-Angiogenic Therapy of Neovascular Age-Related Macular Degeneration

Ranibizumab for Neovascular Age-Related Macular Degeneration

Philip J. Rosenfeld, David M. Brown, Jeffrey S. Heier et al. · New England Journal of Medicine · 2006 · 5.9K citations · Full text

Medicine, Ophthalmology, Surgery +12

Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

David M. Brown, Peter K. Kaiser, Mark Michels et al. · New England Journal of Medicine · 2006 · 3.5K citations

Medicine, Ophthalmology, Pharmacotherapy +13

Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration

Daniel Martín, Maureen G. Maguire, Stuart L. Fine et al. · Ophthalmology · 2012 · 1.7K citations · Full text

Medicine, Ophthalmology, Pharmacotherapy +12

An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular Degeneration

Anne E. Fung, Geeta A. Lalwani, Philip J. Rosenfeld et al. · American Journal of Ophthalmology · 2007 · 972 citations

Medicine, Ophthalmology, Pharmacotherapy +12

A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study

Geeta A. Lalwani, Philip J. Rosenfeld, Anne E. Fung et al. · American Journal of Ophthalmology · 2009 · 884 citations

Medicine, Ophthalmology, Pharmacotherapy +13